Dr. Reddy’s Laboratories has signed a licencing agreement Australia’s Immutep to develop and commercialise the latter’s cancer drug Eftilagimod Alfa (efti) in countries outside North America, Europe, Japan and Greater China.
A late-stage immunotherapy company targeting cancer and autoimmune diseases, Immutep holds global manufacturing rights to the product across all markets. It will supply the product to Dr. Reddy’s in the licenced markets, while retaining all rights, to the product, in the key pharmaceutical markets, including North America, Europe and Japan.
Under the agreement, Immutep will receive from Dr. Reddy’s upfront payment of $20 million. It is also eligible to receive potential regulatory development and commercial milestone payments of up to $349.5 million plus double-digit royalties on commercial sales in these markets.
Efti is its first-in-class novel immunotherapy that directly activates the immune system to fight cancer, which is under evaluation in TACTI-004 (KEYNOTE-F91), a registrational Phase III trial for the first-line therapy of advanced or metastatic non-small cell lung cancer.
Efti is also being investigated in other indications including head & neck cancer, breast cancer, and soft tissue sarcoma, Dr. Reddy’s said.
Published – December 08, 2025 09:31 pm IST
